TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30153790

Group type: EXPERIMENTAL
Intervention: High-dose behavioral treatment (DTI plus relaxation training)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose behavioral treatment (DTI plus relaxation training)
Number of subjects: 20
Study: 30153871

Group type: EXPERIMENTAL
Intervention: Mixed state
Number of subjects: 3918

Group type: EXPERIMENTAL
Intervention: Euthymic state
Number of subjects: 3918

Group type: EXPERIMENTAL
Intervention: Depressed state
Number of subjects: 3918
Study: 30153985

Group type: EXPERIMENTAL
Intervention: Remote patient management
Number of subjects: 1571

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1571
Study: 30154022

Group type: EXPERIMENTAL
Intervention: WHOQOL-BREF questionnaire
Number of subjects: 202
Study: 30154071

Group type: EXPERIMENTAL
Intervention: E-PrEP (social media-based, peer-led intervention)
Number of subjects: 152

Group type: COMPARATOR
Intervention: E-Health (attention-matched general health control condition)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: E-PrEP
Number of subjects: 152
Study: 30154193

Group type: EXPERIMENTAL
Intervention: Intratumoral SD-101 in combination with pembrolizumab
Number of subjects: 22
Study: 30154228

Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor luminespib (formerly AUY922)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EGFR inhibitors (first-, second-, and third-generation)
Number of subjects: 0
Study: 30154229

Group type: EXPERIMENTAL
Intervention: Biannual MRI screening
Number of subjects: 295

Group type: COMPARATOR
Intervention: Annual MG screening plus biannual MRI screening
Number of subjects: 295
Study: 30154857

Group type: EXPERIMENTAL
Intervention: Minilaparotomy hysterectomy (MLH)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Laparoscopic assisted vaginal hysterectomy (LAVH)
Number of subjects: 52
Study: 30154874

Group type: EXPERIMENTAL
Intervention: Asymmetric butterfly prototype nasal dilator strip
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strip (BRNS)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Asymmetric butterfly placebo strip
Number of subjects: 59
Study: 30155268

Group type: EXPERIMENTAL
Intervention: Wii™ Balance Board training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional balance exercises
Number of subjects: 14
Study: 30155282

Group type: EXPERIMENTAL
Intervention: HT (Thealoz Duo®) - sodium hyaluronate and trehalose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HTC-gel (Thealoz Duo Gel) - hyaluronic acid, trehalose, and carbomer
Number of subjects: 0
Study: 30155496

Group type: EXPERIMENTAL
Intervention: Cavitron ultrasonic surgical aspirator (CUSA)
Number of subjects: 11
Study: 30156755

Group type: EXPERIMENTAL
Intervention: Autologous ex vivo expanded EPCs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline or autologous bone marrow stromal cells)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EPC group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo-controlled group
Number of subjects: 18
Study: 30156866

Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study: 30156984

Group type: EXPERIMENTAL
Intervention: Capmatinib (400 mg twice per day) plus Gefitinib (250 mg once per day)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Capmatinib (100-800 mg once per day or 200-600 mg twice per day) plus Gefitinib (250 mg once per day)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Capmatinib plus Gefitinib
Number of subjects: 161
Study: 30157009

Group type: EXPERIMENTAL
Intervention: In-house vocational training program
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Occupational therapists' pursuit of additional training or short-term apprenticeship
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Posttraining vocational counseling provided by community-based occupational therapists
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Duration of 6 months posttraining
Number of subjects: 323
Study: 30157702

Group type: EXPERIMENTAL
Intervention: HPTN 052 clinical trial care and treatment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Reasons for joining the trial
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Transition to public HIV care centers
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Perceived clinical trial care
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Study benefits
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Public HIV care centers' attitude
Number of subjects: 70
Study: 30157791

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 25
Study: 30157803

Group type: EXPERIMENTAL
Intervention: Accelerated BEP chemotherapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard BEP chemotherapy
Number of subjects: 500
Study: 30157867

Group type: EXPERIMENTAL
Intervention: Coping Together (CT) intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Modified Coping Together intervention
Number of subjects: 20
Study: 30157920

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for three months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 30158155

Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 33
Study: 30158223

Group type: EXPERIMENTAL
Intervention: Routine programming attendance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-attendance of programming
Number of subjects: 0
Study: 30158287

Group type: EXPERIMENTAL
Intervention: NETest
Number of subjects: 0
Study: 30158288

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg per day for 56 days
Number of subjects: 19
Study: 30158840

Group type: EXPERIMENTAL
Intervention: Standard therapy with HBOT for 10 sessions (combination therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 30
Study: 30158974

Group type: EXPERIMENTAL
Intervention: Pericardial fat (PERI) measurement in women with PCOS
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy control subjects (no intervention specified)
Number of subjects: 68
Study: 30159001

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (longitudinal estimate)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (cross-sectional prevalence)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Lowest quartile of breastfeeding behaviors
Number of subjects: 125
Study: 30159333

Group type: EXPERIMENTAL
Intervention: Recently diagnosed type 2 diabetes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recently diagnosed type 1 diabetes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metabolically healthy individuals
Number of subjects: 0
Study: 30160030

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 1922

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 1922
Study: 30160363

Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir, ombitasvir + dasabuvir (PTV/r/OBV/DSV) for 8 weeks
Number of subjects: 211
Study: 30160585

Group type: EXPERIMENTAL
Intervention: Park use by women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Park use by men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers for seniors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Park renovations
Number of subjects: 0
Study: 30160804

Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Cachexia
Number of subjects: 207

Group type: COMPARATOR
Intervention: No wasting
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sarcopenia + Cachexia
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sarcopenic HF
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Cachectic HF
Number of subjects: 207
Study: 30161147

Group type: EXPERIMENTAL
Intervention: Option B PMTCT regimen (three-drug ART throughout pregnancy and breastfeeding, regardless of maternal CD4 count)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Option B PMTCT regimen
Number of subjects: 138
Study: 30165119

Group type: EXPERIMENTAL
Intervention: Distress exposure phase with visual stimuli (Besancon Affective Picture Set-Adolescents)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Comfort-seeking phase with visual stimuli
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Neurophysiological parameters
Number of subjects: 81
Study: 30165185

Group type: EXPERIMENTAL
Intervention: Intraoperative superior hypogastric plexus (SHP) block (Hypo; n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intraoperative SHP block (No-Hypo; n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 30165500

Group type: EXPERIMENTAL
Intervention: Vegetable consumption
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fruit consumption
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fruit consumption in RTRs with eGFR > 45 mL/min/1.73 m2
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fruit consumption in RTRs without proteinuria
Number of subjects: 400
Study: 30165521

Group type: EXPERIMENTAL
Intervention: HeartMate 3™ (HM3) LVAD
Number of subjects: 463
Study: 30165570

Group type: EXPERIMENTAL
Intervention: eGFR estimated from serum creatinine
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: eGFR estimated from serum cystatin C
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: eGFR estimated from both serum creatinine and cystatin C
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Urinary albumin-to-creatinine ratio (ACR)
Number of subjects: 447
Study: 30165599

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid (high-MUFA) diet
Number of subjects: 980

Group type: COMPARATOR
Intervention: High-carbohydrate (high-CHO) diet
Number of subjects: 980
Study: 30165651

Group type: EXPERIMENTAL
Intervention: Second dose of live herpes zoster vaccine (ZVL)
Number of subjects: 2

Group type: COMPARATOR
Intervention: De novo immunization
Number of subjects: 2
Study: 30165822

Group type: EXPERIMENTAL
Intervention: Educational intervention for hospital staff
Number of subjects: 0
Study: 30165894

Group type: EXPERIMENTAL
Intervention: Inverted internal limiting membrane insertion plus air tamponade
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional vitrectomy plus internal limiting membrane peeling plus silicone oil tamponade
Number of subjects: 38
Study: 30166073

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily) plus aspirin (75-100 mg daily) for 1 month, followed by ticagrelor monotherapy for 23 months
Number of subjects: 15968

Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (75-100 mg aspirin daily plus either 75 mg clopidogrel daily or 90 mg ticagrelor twice daily for 12 months), followed by aspirin monotherapy for 12 months
Number of subjects: 15968
Study: 30166253

Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r plus RIB) for 12 weeks
Number of subjects: 110
Study: 30166274

Group type: EXPERIMENTAL
Intervention: 6-month physical activity program with activity tracker (Nokia Go)
Number of subjects: 60
Study: 30166291

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) syndrome-targeted therapies
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) four diagnostic methods
Number of subjects: 2000
Study: 30166293

Group type: EXPERIMENTAL
Intervention: TRANSIMMUNOM observational clinical protocol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Systems biology approaches
Number of subjects: 25
Study: 30166295

Group type: EXPERIMENTAL
Intervention: Post-CABG 24 hours urinary TXA-M
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Intermediate tertile of post-CABG 24 hours urinary TXA-M
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: Upper tertile of post-CABG 24 hours urinary TXA-M
Number of subjects: 1670
Study: 30167089

Group type: EXPERIMENTAL
Intervention: Alpelisib (300 mg, n=6) plus paclitaxel (80 mg/m2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Alpelisib (250 mg, n=4) plus paclitaxel (80 mg/m2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Alpelisib (150 mg, n=9) plus paclitaxel (80 mg/m2)
Number of subjects: 19
Study: 30167310

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg two times a day
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 30167329

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 460
Study: 30167756

Group type: COMPARATOR
Intervention: OAT4
Number of subjects: 60

Group type: COMPARATOR
Intervention: OCT2
Number of subjects: 60

Group type: COMPARATOR
Intervention: OCT3
Number of subjects: 60

Group type: COMPARATOR
Intervention: PEPT2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OAT4-transfected cells
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEPT2-transfected cells
Number of subjects: 60

Group type: COMPARATOR
Intervention: OAT4 and PEPT2 genotypes
Number of subjects: 60
Study: 30167809

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR) for detection of AF
Number of subjects: 173
Study: 30168083

Group type: EXPERIMENTAL
Intervention: In-centre nocturnal hemodialysis (INHD, 7-8 h/session, 3×/week)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional hemodialysis (CHD, 4 h/session, 3×/week)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups (INHD and CHD)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Changes in LA and LV end-diastolic volume index (EDVi)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Changes in LA and LV end-systolic volume index (ESVi)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Changes in LA EF and LVEF
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Changes in LA and RV EDVi
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Changes in LA and RV ESVi
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Changes in LA ESVi and LV mass index
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Indexed LA volumes at baseline
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: LA EF at baseline
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Changes in biomarker levels after 52 weeks
Number of subjects: 67
Study: 30168134

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1·8 mg/kg intravenously once every 3 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 60
Study: 30168233

Group type: EXPERIMENTAL
Intervention: Micra TPS implantation
Number of subjects: 720
Study: 30168356

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) in addition to physiotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Physiotherapy (PT) only
Number of subjects: 23
Study: 30168744

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment Tool
Number of subjects: 0
Study: 30169182

Group type: EXPERIMENTAL
Intervention: AAV2-hAADC gene therapy (bilateral intraputaminal injections, dosage not specified)
Number of subjects: 10
Study: 30169223

Group type: EXPERIMENTAL
Intervention: Elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily
Number of subjects: 23
Study: 30169354

Group type: EXPERIMENTAL
Intervention: BrainPort Vision Pro
Number of subjects: 17
Study: 30169606

Group type: EXPERIMENTAL
Intervention: Geographical allocation of interventions focusing on hotspots of HIV transmission
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Geospatial analyses
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Slatkin-Maddison analyses
Number of subjects: 714
Study: 30169669

Group type: EXPERIMENTAL
Intervention: Maternal and neonatal vitamin D status (25(OH)D concentrations)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Low antenatal vitamin D status (<30 nmol/L and <50 nmol/L)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Maternal 25(OH)D (per 10 nmol/L)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Cord 25(OH)D (per 10 nmol/L)
Number of subjects: 734
Study: 30169719

Group type: EXPERIMENTAL
Intervention: Authoritative feeding style
Number of subjects: 0

Group type: COMPARATOR
Intervention: Authoritarian feeding style
Number of subjects: 0
Study: 30169752

Group type: EXPERIMENTAL
Intervention: ESC hs-cTnT 0/1h-algorithm in young patients
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: ESC hs-cTnT 0/1h-algorithm in middle-age patients
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: ESC hs-cTnT 0/1h-algorithm in old patients
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: Alternative higher cut-off concentrations for older patients
Number of subjects: 2767
Study: 30170075

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 200

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 200
Study: 30170561

Group type: EXPERIMENTAL
Intervention: Heckman's model for MNAR outcomes
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Developed imputation approach
Number of subjects: 500

Group type: COMPARATOR
Intervention: Complete case approach
Number of subjects: 500

Group type: COMPARATOR
Intervention: Classical Heckman's model estimates
Number of subjects: 500
Study: 30170575

Group type: EXPERIMENTAL
Intervention: Palliative care provision, quality of life and death, elements of advance care planning, family caregivers' needs and satisfaction
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Expert-consensus recommendations derived from the study results
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Communication of recommendations nationally and internationally
Number of subjects: 200
Study: 30170630

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) and low-dose ipilimumab (1 mg/kg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Empiric immune suppressive therapy (high dose steroids, tacrolimus, therapeutic plasma exchange)
Number of subjects: 1
Study: 30170807

Group type: EXPERIMENTAL
Intervention: GOLD 2017 stage C
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: GOLD 2017 stage D
Number of subjects: 959
Study: 30170997

Group type: EXPERIMENTAL
Intervention: Presence of preoperative self-reported mechanical knee symptoms
Number of subjects: 641
Study: 30171081

Group type: EXPERIMENTAL
Intervention: Ravulizumab 900 mg every 4 weeks (lower trough exposure)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ravulizumab 1800 mg every 4 weeks (higher trough exposure)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ravulizumab 1000 mg every 4 weeks, 1600 mg every 6 weeks, 2400 mg every 8 weeks, or 5400 mg every 12 weeks (study 201)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ravulizumab (all cohorts)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ravulizumab (higher-trough-exposure cohort)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ravulizumab (lower-trough-exposure cohorts)
Number of subjects: 39
Study: 30171354

Group type: EXPERIMENTAL
Intervention: Creatinine-based equations for estimating GFR
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cystatin C-based equations for estimating GFR
Number of subjects: 96

Group type: COMPARATOR
Intervention: Measured GFR (mGFR) by iohexol clearance
Number of subjects: 96
Study: 30171779

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily on Days 3-32 and simvastatin 40 mg single doses on Days 1 and 31
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily on Days 4-34 and rosuvastatin 20 mg single doses on Days 1 and 32
Number of subjects: 52
Study: 30171797

Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella vaccine (MMR)
Number of subjects: 44
Study: 30172032

Group type: EXPERIMENTAL
Intervention: Secretory leukocyte protease inhibitor (SLPI)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Donor IL-6
Number of subjects: 556

Group type: COMPARATOR
Intervention: Clinical variables alone
Number of subjects: 556
Study: 30172345

Group type: EXPERIMENTAL
Intervention: R2-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone + 25 mg oral Lenalidomide per day on days 1-14 for 6 cycles every 3 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: R2-CHOP
Number of subjects: 80
Study: 30172739

Group type: EXPERIMENTAL
Intervention: Estimated antipsychotic dopamine receptor occupancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Premorbid IQ and cognition
Number of subjects: 0
Study: 30173210

Group type: EXPERIMENTAL
Intervention: Intracavernous autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) injections
Number of subjects: 4
Study: 30174209

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB
Number of subjects: 9610

Group type: EXPERIMENTAL
Intervention: TST-15
Number of subjects: 9610

Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold In-Tube
Number of subjects: 9610

Group type: COMPARATOR
Intervention: TST-10
Number of subjects: 9610

Group type: COMPARATOR
Intervention: TST-5
Number of subjects: 9610
Study: 30174861

Group type: EXPERIMENTAL
Intervention: ctDNA based EGFR mutation test
Number of subjects: 1001
Study: 30174890

Group type: EXPERIMENTAL
Intervention: Preoperative ALI
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Preoperative Diastolic Blood Pressure (DBP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Prostaglandin I2/TXB2 ratio
Number of subjects: 130
Study: 30174920

Group type: EXPERIMENTAL
Intervention: PACK Adult clinical decision support tool with educational outreach training for doctors and nurses
Number of subjects: 48

Group type: COMPARATOR
Intervention: PACK Adult clinical decision support tool
Number of subjects: 48
Study: 30174951

Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg and pregabalin 150mg 1 hour before the operation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg and pregabalin 75mg twice daily starting from 3 days before the operation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 30
Study: 30174959

Group type: EXPERIMENTAL
Intervention: PEEK Interspinous Spacer (IS)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Silicon Interspinous Spacer (IS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no IS)
Number of subjects: 55